Chinas weight-loss drug makers take on global giants as Novo Nordisk patent expires Patent expiry of blockbuster drug opens door for Chinese drug makers to challenge multinationals in booming weight-loss market Novo Nordisks blockbuster semaglutide, which generated about US$35 billion in global revenue last year, lost patent protection in China on March 20, clearing the way for rivals
Liu Y, Gou L, Fu X, Li S, Lan N, Yin X (2013) Protective effect of rutin against acute gastric mucosal lesions induced by ischemia-reperfusion
Good Candidate for Semaglutide Semaglutide is an FDA-approved medication specifically designed for adult weight management
The approach is intended to build on the mechanisms of existing incretin-based obesity medicines, including Lilly's dual GIP/GLP-1 agonist tirzepatide
This results in harder, drier stools that are more difficult for your body to pass
Takeaway 1: Instead of Worsening Depression, Scores Actually Improved A primary concern is that these medications could trigger or worsen depression